Quanterix

QTRX

Market cap $164M

LAGUNA HILLS, Calif. & BILLERICA, Mass.--(BUSINESS WIRE)--PreludeDx® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on Akoya PhenoImager® HT platform using Opal™ chemistry. This marks a significant milestone in the clinical translation of spatial proteomics. The validation of AidaBREAST included 922 hormone recep.

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX) today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026. Built on the integration of Akoya Biosciences' spatial biology platform and Quanterix's decades of ultra-sensitive, quantitative immunoassay development from the SIMOA® technology, the Content Innovation Engine is organized around the hallmarks of cancer framework, giving researchers a sys.

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Company's 2026 annual meeting of shareholders (the “Annual Meeting”) will be held virtually, by means of remote communication, on Tuesday, June 9, 2026 at 10:00 am Eastern Time. Stockholders of record of the Company's common stock as of the close of business on April 14, 2026 will be entitled to vote.

Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.3 per share a year ago.

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter and full year ended December 31, 2025. “I am thrilled to be joining Quanterix at a time when the company is well-positioned to deliver long-term growth,” said Everett Cunningham, President & CEO of Quanterix. “During the fourth quarter, we exceeded our revenue expectations, we con.

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the partnership, Life Line Screening will offer Lucent's non-invasive blood based biomarker test nationally, with programs in Florida, California, and Texas already underway. This partnership supports the g.

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor conferences in March: 46th Annual TD Cowen Healthcare Conference Format: Fireside chat and one-on-one meetings Date: Wednesday, March 4, 2026 Time: 11:50 am ET Webcast: Click here Leerink Global Healthcare Conference 2026 Forma.

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2025 financial results. Quanterix will issue a press release regarding its fourth quarter and full year 2025 financial results prior to the conference call on Monday, March 2, 2026.

QTRX submits a 510(k) to the FDA for its multi-analyte blood test aimed at evaluating cognitive symptoms for possible Alzheimer's disease.